Camostat (mesylate) (Standard)

Camostat (mesylate) (Standard) is the analytical standard of Camostat (mesylate) . This product is intended for research and analytical applications. Camostat mesylate (Camostat mesilate) is an orally active, synthetic serine protease inhibitor for chronic pancreatitis. Camostat mesylate, an inhibitor of TMPRSS2, shows antiviral activity against SARS-CoV-2. Camostat mesylate also inhibits the activity of prostasin, trypsin, and matriptase[1][2][3].

Product Specifications

CAS Number

[59721-29-8]

Product Name Alternative

Camostat mesilate (Standard) ; FOY305 (Standard) ; FOY-S980 (Standard)

UNSPSC

12352005

Hazard Statement

H315, H319, H335, H400

Target

Reference Standards; SARS-CoV; Ser/Thr Protease

Type

Reference Standards

Related Pathways

Anti-infection; Metabolic Enzyme/Protease; Others

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/camostat-mesylate-standard.html

Purity

99.96

Smiles

O=C(OCC(N(C)C)=O)CC1=CC=C(OC(C2=CC=C(NC(N)=N)C=C2)=O)C=C1.CS(=O)(O)=O

Molecular Formula

C21H26N4O8S

Molecular Weight

494.52

Precautions

H315, H319, H335, H400

References & Citations

[1]Gibo J, et al. Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity. Lab Invest. 2005;85 (1) :75‐89.|[2]Uno Y. Camostat mesilate therapy for COVID-19 [published online ahead of print, 2020 Apr 29]. Intern Emerg Med. 2020;1‐2.|[3]Coote K, et al. Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease. J Pharmacol Exp Ther. 2009;329 (2) :764‐774.|[4]Zhou Y, Vedantham P, Lu K, et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 2015;116:76‐84.